Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
In: Journal of Hematology & Oncology Journal of Hematology & Oncology, Jg. 9 (2016), Heft 1, S. 1-4
Online
unknown
Zugriff:
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib.
Titel: |
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|
---|---|
Autor/in / Beteiligte Person: | Liu, Delong ; Zhang, Mingzhi ; Wu, Jingjing |
Link: | |
Zeitschrift: | Journal of Hematology & Oncology Journal of Hematology & Oncology, Jg. 9 (2016), Heft 1, S. 1-4 |
Veröffentlichung: | BioMed Central, 2016 |
Medientyp: | unknown |
ISSN: | 1756-8722 (print) |
Schlagwort: |
|
Sonstiges: |
|